Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...2627282930313233343536...858859»
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  Schisandrin C prevents Regorafenib-Induced cardiotoxicity by recovering EPHA2 expression in cardiomyocytes. (Pubmed Central) -  Sep 30, 2024   
    In addition, we showed that recovering EPHA2 expression via plasmid-induced overexpression of EPHA2 or schisandrin C, a natural product, could prevent regorafenib-induced cardiotoxicity. These findings demonstrated that regorafenib causes cardiomyocyte apoptosis and cardiac injury by reducing the expression of EPHA2 and schisandrin C could prevent regorafenib-induced cardiotoxicity by recovering EPHA2 expression, which provides a potential management strategy for regorafenib-induced cardiotoxicity and will benefit the safe application of regorafenib in clinic.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Autologous platelet concentrates as adjuvant in the surgical management of medication-related osteonecrosis of the jaw. (Pubmed Central) -  Sep 30, 2024   
    Medication-related osteonecrosis of the jaw (MRONJ) is an infectious side effect associated with bisphosphonates and monoclonal antibodies (denosumab, immune modulators, and antiangiogenic medications)...The overall results of this review have shown favorable healing rates of MRONJ lesions managed with the application of APCs after surgical treatment; however, significant methodological limitations may limit the scientific evidence supporting their use. Further randomized controlled trials with strict criteria are needed to establish the extent to which APCs can improve wound healing and quality of life in patients with MRONJ requiring surgical treatment.
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi
    Review, Journal, Tumor cell:  Cancer Metastases to the Liver: Mechanisms of Tumor Cell Colonization. (Pubmed Central) -  Sep 29, 2024   
    Finally, we discuss the significance of non-pharmacological methods, including surgical procedures, radiotherapy, cryotherapy, radiofrequency ablation (RFA), and transarterial embolization (TAE). In conclusion, the given methods can successfully prevent metastases to the liver and prolong the median survival duration and median overall survival in patients suffering from cancer.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Clinical, Journal, Real-world evidence, Real-world:  Real-World Data with CDK4/6 Inhibitors-A Single Center Experience from Croatia. (Pubmed Central) -  Sep 29, 2024   
    Our study provides the RWD with the use of CDK4/6 inhibitors in the treatment of metastatic HR+/HER2- breast cancer. To our best knowledge, there are limited RWD regarding CDK 4/6 inhibitors use in western Balkan; thus, our study provides valuable data from everyday clinical practice for this region of Europe, bridging the gap between randomized clinical trials and clinical reality in western Balkan.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    SEVERE EGPA ? A ROLE FOR TEZEPELUMAB? (Monitor 12; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1156;    
    Further study is needed to elucidate whether there may be a broader role for allergic pathway blockade in the treatment paradigms for EGPA. Figure 1 Diagnostics including labs, imaging, and procedures
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
    REFRACTORY ASTHMA UNVEILING HISTOPLASMOSIS: A DIAGNOSTIC CHALLENGE (Monitor 7; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_973;    
    She has tolerated tezepelumab with open triple therapy however was hospitalized for respiratory distress in October 2023...After three months of itraconazole in addition to her asthma therapies, her histoplasmosis levels returned negative and itraconazole was discontinued...This report aims to explore the diagnostic and management considerations in cases where severe asthma and histoplasmosis co-occur, providing insights into their therapy. Clinical Immunology, Immunodeficiency
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    ENHANCED LUNG FUNCTION IN A PATIENT WITH CYSTIC FIBROSIS AND ABPA TREATED WITH TEZEPELUMAB (Monitor 7; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_927;    
    Via its mechanism targeting thymic stromal lymphoprotein (TSLP), an upstream alarmin important for epithelial barrier integrity and mucus production, tezepelumab presents an attractive option for cystic fibrosis patients with concomitant allergic pulmonary disease. More research is needed to determine if tezepelumab is safe and effective in these patients.
  • ||||||||||  DUAL BIOLOGIC USE IN SEVERE EOSINOPHILIC ASTHMA (Monitor 7; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_665;    
    His AEC remained low at 100/ uL, FeNO normalized to 10ppb, and lung function improved. : The complementary use of asthma biologics with different targets in the T2 inflammatory cascade may be a viable solution for patients intolerant or non-responsive to a single drug.
  • ||||||||||  omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Journal:  Myosin Isoform-Dependent Effect of Omecamtiv Mecarbil on the Regulation of Force Generation in Human Cardiac Muscle. (Pubmed Central) -  Sep 29, 2024   
    Interestingly, in the ventricle, but not in the atrium, OM induced a large dose-dependent Ca2+-independent force development and an increase in basal ATPase that were abolished by the presence of millimolar inorganic phosphate, consistent with the hypothesis that the widely reported Ca2+-sensitising effect of OM may be coupled to a change in the state of the thick filaments that resembles the on-off regulation of thin filaments by Ca2+. The complexity of this scenario may help to understand the disappointing results of clinical trials testing OM as inotropic support in systolic heart failure compared with currently available inotropic drugs that alter the calcium signalling cascade.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Journal:  Dacryoadenitis occurring during treatment with Etanercept. (Pubmed Central) -  Sep 28, 2024   
    This study included high-quality multicenter Phase III RCTs, collated and summarized all treatments involved in advanced or unresectable HCC in first-line and second-line settings, and compared with T+A and regorafenib, respectively, and ranked based on efficacy and safety to support clinical decision making. No abstract available
  • ||||||||||  Neulasta (pegfilgrastim) / Roche
    Case Report of a 18F-FDG PET/CT after Pegfilgrastim Administration (e-Poster Area) -  Sep 27, 2024 - Abstract #EANM2024EANM_2582;    
    The patient was undergoing preoperative doxorubicin hydrochloride and cyclophosphamide chemotherapy, and because of neutropenia as a side effect, was given pegfilgastrim on day 2 after each cycle of chemotherapy. Pegfilgastrim increased bone marrow uptake of 18F-FDG because of pegfilgrastim-induced stimulation of neutrophil progenitor cells, and therefore a change in 18F-FDG biodistribution must be considered before quantitative assessment of PET scans.
  • ||||||||||  Pluvicto (lutetium Lu 177 vipivotide tetraxetan) / Novartis
    Factors Influencing Clinical and Biological Response in Patients Treated with [177Lu]Lu-PSMA-617 under France's early access program. (e-Poster Area) -  Sep 27, 2024 - Abstract #EANM2024EANM_2086;    
    No significant differences (p>0.05) were observed between the responders and the non-responders with respect to patient age, ECOG score, initial PSA levels, metastasis locations, the number of previous NHT, the number of lines of taxane-based chemotherapy, and treatments received such as external radiotherapy, bisphosphonates, denosumab or immunotherapy. The response to [177Lu]Lu-PSMA-617 may be influenced by the number of [177Lu]Lu-PSMA-617 cycles administered, PSMA-PET lesion positivity and concurrent NHT administration.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, Herceptin (trastuzumab) / Roche, Vectibix (panitumumab) / Amgen
    A fully automated process and a generic kit to reduce development and production costs of [89Zr]mABs in clinical trial settings (Hall X1-X4) -  Sep 27, 2024 - Abstract #EANM2024EANM_557;    
    The developed process offers a cost-effective approach to the use of [89Zr]mABs in clinical trials while allowing for an effortless transfer to subsequent routine production. The process is compatible with potentially any mAB-DFO conjugate, with both PD-10 and HiTrap purification cartridges, a wide range of 89Zr-oxalate volumes and concentrations while delivering state-of-the-art production yields.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Evaluating Treatment Modalities for Reducing Recurrence in Central Giant Cell Granuloma: A Narrative Review. (Pubmed Central) -  Sep 27, 2024   
    Twenty-nine studies were reviewed, including six studies on surgical excision and curettage, eight studies on intralesional corticosteroid injections, six studies on calcitonin therapy, five studies on interferon-alpha therapy, and four studies on the therapy with denosumab...Aggressive surgical excision combined with nonsurgical methods may lower recurrence rates, while conservative techniques remain viable in some cases. Further prospective research is needed to validate these findings and enhance CGCG treatment options.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal, Adverse events, Real-world evidence, Real-world:  A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab. (Pubmed Central) -  Sep 27, 2024   
    These findings underscore the critical importance of pharmacovigilance and are consistent with established clinical observations. Notably, osteonecrosis of the jaw, arthralgia, pain in extremities, back pain, myalgia, and bone pain were identified as the most prevalent risk signals associated with denosumab.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Enrollment open:  Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial) (clinicaltrials.gov) -  Sep 27, 2024   
    P2,  N=104, Recruiting, 
    This report shows that the novel combination of ponatinib and asciminib is tolerable and effective as a bridge and maintenance therapy after brexu-cel. Not yet recruiting --> Recruiting
  • ||||||||||  P2 data, P3 data, Review, Journal:  Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials. (Pubmed Central) -  Sep 26, 2024   
    Clinical trials for 36 agents currently in phase 2 or phase 3 are evaluated with particular focus on the studies for, B244, CBP-201, Tapinarof, Lebrikizumab, Nemolizumab, Amlitelimab, and Rocatinlimab as they explore novel pathways and have some of the most promising results. These clinical trials contribute to the evolution of AD treatment toward greater precision based on salient pathways with a particular focus on moderate-to-severe AD to enhance efficacy and minimize adverse effects.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal:  Short-term Tezepelumab effectiveness in patients with severe asthma: a multicentre study. (Pubmed Central) -  Sep 26, 2024   
    Tezepelumab demonstrated short-term efficacy in improving asthma control and quality of life, showing a favourable safety profile. Further studies with larger sample sizes and longer follow-up would confirm these findings and identify predictors of response to Tezepelumab.
  • ||||||||||  ivabradine / Generic mfg.
    Preclinical, Journal:  A Photoactivatable Version of Ivabradine Enables Light-Induced Block of HCN Current In Vivo. (Pubmed Central) -  Sep 26, 2024   
    Caging is stable in aqueous medium and in the dark, and it does not impair aqueous solubility and cell permeation, indispensable for IVA activity. This approach allows for bypassing the poor subtype-specificity of IVA, expanding its prescription to HCN-related diseases besides cardiac.